All Stories

  1. Malignant hypertension due to defective complement regulation

    Article • Journal of Clinical Hypertension, September 2015, Wiley

    Dr Han Mou Tsai

  2. Acquired Thrombotic Thrombocytopenic Purpura

    Article • January 2015, Springer Science + Business Media

    Dr Han Mou Tsai

  3. A Mechanistic Approach to the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome

    Article • Transfusion Medicine Reviews, October 2014, Elsevier

    Dr Han Mou Tsai

  4. Repair of Nanodefects in a Two-Dimensional Crystal Anticoagulant Shield in the Antiphospholipid Syndrome

    Article • April 2014, Taylor & Francis

    Dr Han Mou Tsai

  5. Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

    Article • Advances in Hematology, January 2014, Hindawi Publishing Corporation

    Dr Han Mou Tsai

  6. Thrombotic Thrombocytopenic Purpura and the Atypical Hemolytic Uremic Syndrome

    Article • Hematology/Oncology Clinics of North America, June 2013, Elsevier

    Dr Han Mou Tsai

  7. Concurrent atypical hemolytic uremic syndrome in a case of "refractory" thrombocytopenic purpura

    Article • British Journal of Haematology, May 2013, Wiley

    Dr Han Mou Tsai

  8. Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome

    Article • The American Journal of Medicine, March 2013, Elsevier

    Dr Han Mou Tsai

  9. Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome

    Article • January 2013, Elsevier

    Dr Han Mou Tsai

  10. Autoimmune Thrombotic Microangiopathy: Advances in Pathogenesis, Diagnosis, and Management

    Article • Seminars in Thrombosis and Hemostasis, April 2012, Thieme Publishing Group

    Dr Han Mou Tsai

  11. von Willebrand Factor, Shear Stress, and ADAMTS13 in Hemostasis and Thrombosis

    Article • ASAIO Journal, February 2012, Wolters Kluwer Health

    Dr Han Mou Tsai

  12. Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time?

    Article • Kidney International, February 2010, Elsevier

    Dr Han Mou Tsai

  13. Pathophysiology of thrombotic thrombocytopenic purpura

    Article • International Journal of Hematology, January 2010, Springer Science + Business Media

    Dr Han Mou Tsai

  14. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura

    Article • Kidney International, February 2009, Elsevier

    Dr Han Mou Tsai

  15. Thrombotic Thrombocytopenic Purpura: A Thrombotic Disorder Caused by ADAMTS13 Deficiency

    Article • Hematology/Oncology Clinics of North America, August 2007, Elsevier

    Dr Han Mou Tsai

  16. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura

    Article • European Journal of Pediatrics, December 2006, Springer Science + Business Media

    Dr Han Mou Tsai

  17. ADAMTS13 and microvascular thrombosis

    Article • Expert Review of Cardiovascular Therapy, November 2006, Taylor & Francis

    Dr Han Mou Tsai

  18. Multifunctional Composite Nanoparticles:  Magnetic, Luminescent, and Mesoporous

    Article • Chemistry of Materials, October 2006, American Chemical Society (ACS)

    Dr Han Mou Tsai

  19. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura

    Article • Thrombosis and Haemostasis, April 2006, Schattauer GmbH

    Dr Han Mou Tsai

  20. Current Concepts in Thrombotic Thrombocytopenic Purpura

    Article • Annual Review of Medicine, February 2006, Annual Reviews

    Dr Han Mou Tsai

  21. ADAMTS13 is expressed in hepatic stellate cells

    Article • Laboratory Investigation, April 2005, Nature

    Dr Han Mou Tsai

  22. Why Do We Need ADAMTS13?

    Article • Japanese Journal of Thrombosis and Hemostasis, January 2005, Japanese Society on Thrombosis and Hemostasis

    Dr Han Mou Tsai

  23. Molecular Mechanisms in Thrombotic Thrombocytopenic Purpura

    Article • Seminars in Thrombosis and Hemostasis, October 2004, Thieme Publishing Group

    Dr Han Mou Tsai

  24. Thrombocytopenia and Severe Hyperbilirubinemia in the Neonatal Period Secondary to Congenital Thrombotic Thrombocytopenic Purpura and ADAMTS13 Deficiency

    Article • Journal of Pediatric Hematology/Oncology, August 2004, Wolters Kluwer Health

    Dr Han Mou Tsai

  25. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations

    Article • Thrombosis and Haemostasis, February 2004, Schattauer GmbH

    Dr Han Mou Tsai

  26. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

    Article • British Journal of Haematology, February 2004, Wiley

    Dr Han Mou Tsai

  27. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura

    Article • European Journal Of Haematology, February 2003, Wiley

    Dr Han Mou Tsai

  28. Thrombotic Thrombocytopenic Purpura in a Newborn

    Article • Journal of Perinatology, January 2003, Nature

    Dr Han Mou Tsai

  29. Presence of ADAMTS13 Activity in a Patient with Metastatic Cancer and Thrombotic Microangiopathy

    Article • Acta Haematologica, January 2003, Karger Publishers

    Dr Han Mou Tsai

  30. Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood

    Article • Thrombosis Research, November 2002, Elsevier

    Dr Han Mou Tsai

  31. Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura

    Article • Transfusion, November 2002, Wiley

    Dr Han Mou Tsai

  32. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

    Article • Journal of Molecular Medicine, October 2002, Springer Science + Business Media

    Dr Han Mou Tsai

  33. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient

    Article • Transplantation, October 2002, Wolters Kluwer Health

    Dr Han Mou Tsai

  34. Transfusion of polymerised human haemoglobin in a patient with severe sickle-cell anaemia

    Article • The Lancet, August 2002, Elsevier

    Dr Han Mou Tsai

  35. Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura

    Article • International Journal of Hematology, March 2002, Springer Science + Business Media

    Dr Han Mou Tsai

  36. Warm-Antibody Autoimmune Hemolytic Anemia Developing after Thrombotic Thrombocytopenic Purpura

    Article • Acta Haematologica, January 2002, Karger Publishers

    Dr Han Mou Tsai

  37. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

    Article • Nature, October 2001, Nature

    Dr Han Mou Tsai

  38. Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome

    Article • Pediatric Research, May 2001, Nature

    Dr Han Mou Tsai

  39. A comparison of von Willebrand Factor antigen with platelet activity in vitro in normal and venous occlusion blood

    Article • Platelets, January 2001, Taylor & Francis

    Dr Han Mou Tsai

  40. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy

    Article • The Hematology Journal, January 2001, Nature

    Dr Han Mou Tsai

  41. Surface dependent structures of von Willebrand factor observed by AFM under aqueous conditions

    Article • Colloids and Surfaces B Biointerfaces, December 2000, Elsevier

    Dr Han Mou Tsai

  42. Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel

    Article • New England Journal of Medicine, June 2000, New England Journal of Medicine (NEJM/MMS)

    Dr Han Mou Tsai

  43. Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor

    Article • British Journal of Haematology, June 2000, Wiley

    Dr Han Mou Tsai

  44. Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura

    Article • Annals of Internal Medicine, May 2000, American College of Physicians

    Dr Han Mou Tsai

  45. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura

    Article • American Journal of Hematology, January 2000, Wiley

    Dr Han Mou Tsai

  46. Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura

    Article • New England Journal of Medicine, November 1998, New England Journal of Medicine (NEJM/MMS)

    Dr Han Mou Tsai

  47. The high molecular weight form of endothelial cell von Willebrand factor is released by the regulated pathway

    Article • British Journal of Haematology, October 1991, Wiley

    Dr Han Mou Tsai

  48. Subunit composition of plasma von Willebrand factor multimers: Evidence for a non-proteolytic mechanism resulting in apparent increase in proteolytic fragments

    Article • Thrombosis Research, July 1991, Elsevier

    Dr Han Mou Tsai

  49. Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases

    Article • Biochemical and Biophysical Research Communications, February 1989, Elsevier

    Dr Han Mou Tsai

  50. ADAMTS-13

    Article • Springer Science + Business Media

    Dr Han Mou Tsai